ICON8B: A trial looking at chemotherapy weekly with bevacizumab versus three weekly with bevacizumab for advanced ovarian cancer
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you:
- epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
- a cancer that is staged as high risk
- good overall levels of fitness and satisfactory blood test results
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
The study aims to find out the answers to the following questions:
- Is one of these treatment approaches better than the other?
- Which treatment causes fewer side effects?
- Which treatment offers a better quality of life?
- Is it safe to use bevacizumab to treat women who are having surgery at the same time as chemotherapy?
If you take part in this study, you'll be randomised (placed into a treatment group by a computer) into one of two treatment groups:
- Group B1 – you'll receive chemotherapy and bevacizumab at weekly intervals. Participants in this group will receive 18 weeks of:
- carboplatin once every three weeks
- paclitaxel once every three weeks
- bevacizumab once every three weeks followed by bevacizumab continuing alone for approximately 11 months
- Group B3 – you'll receive chemotherapy and bevacizumab at three weekly intervals. Participants in this group will receive 18 weeks of:
- carboplatin once every three weeks
- paclitaxel once every week (on days one, eight and 15 of a three-weekly cycle)
- bevacizumab once every three weeks followed by bevacizumab continuing alone for approximately 11 months